Based on the important role of BRD4 in regulating leukemia gene transcription along with NF-κB, BRD4 specific inhibitors JQ1 (thieno-triazolo-1,4-diazepine) and IBET-151 have been tested for AML treatment. Here, NFKB1 is linked to acute myeloid leukemia.